Cell and gene therapy CDMO ProBio officially announced the opening of its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, New Jersey.
The 128,000-square-foot GMP facility will make high-quality plasmid DNA and viral vectors, including AAV and lentiviral platforms. The enhancements will enable ProBio to support a broader range of therapeutic candidates from early proof-of-concept through clinical readiness, all from one integrated site.
Back in April, ProBio launched the facility’s plasmid DNA manufacturing service — delivering clinical-grade plasmid DNA production from cell bank to batch release in three months. GMP AAV manufacturing is expected to launch by Q3 2025, followed by GMP LVV services in Q1 2026.
The Hopewell facility serves as the company's North American hub, designed to support and complement its broader operations across North America and Europe.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!